285 related articles for article (PubMed ID: 35671877)
1. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
6. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies in non-metastatic gastrointestinal cancers.
Saúde-Conde R; Nguyen D; Hendlisz A
Curr Opin Oncol; 2023 Jul; 35(4):334-346. PubMed ID: 37222204
[TBL] [Abstract][Full Text] [Related]
8. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies.
Harrold EC; Keane F; Cercek A
Clin Adv Hematol Oncol; 2024 May; 22(4):162-173. PubMed ID: 38739719
[TBL] [Abstract][Full Text] [Related]
11. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T; Frost N; Sommer L; Overbeck TR; Michaeli CT; Szuszies CJ; Rieckmann LM; Beumer N; Imbusch CD; Winter H; Thomas M; Roeper J; Janning M; Griesinger F; Wermke M; Loges S
Lung Cancer; 2022 Feb; 164():46-51. PubMed ID: 34998106
[TBL] [Abstract][Full Text] [Related]
12. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.
Benitez JC; Remon J; Besse B
Clin Cancer Res; 2020 Oct; 26(19):5068-5077. PubMed ID: 32434852
[TBL] [Abstract][Full Text] [Related]
13. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
14. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Fisher KW; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Int Immunopharmacol; 2022 May; 106():108628. PubMed ID: 35203041
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Conroy MR; Dennehy C; Forde PM
Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
[TBL] [Abstract][Full Text] [Related]
17. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
Peng Y; Li Z; Fu Y; Pan Y; Zeng Y; Liu J; Xiao C; Zhang Y; Su Y; Li G; Wu F
Front Oncol; 2023; 13():1011810. PubMed ID: 36761954
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]